Compare BIO-TECHNE Corp (TECH) vs TORM plc (TRMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs TORM plc — how do they compare? BIO-TECHNE Corp trades at $71.63 (market cap $11.16B), while TORM plc trades at $29.89 (market cap $2.99B). The key difference: BIO-TECHNE Corp is far larger — about 3.7× TORM plc's market cap, and TORM plc pays the higher dividend (9.62%). Which is the better fit depends on your goals.
| TECH | TRMD | |
|---|---|---|
Market Cap | $11.16B | $2.99B |
Sector | Health | Technology |
52-Week High | $72.12 | $34.87 |
52-Week Low | $43.31 | $17.50 |
Enterprise Value | $11.24B | $3.88B |
Dividend Yield | 0.45% | 9.62% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
TRMD trades at $29.08, up 2.21% today, with a neutral technical signal. The company reported strong profitability with a 24.41% net income margin and a low P/E of 8.34. Recent earnings showed a Q1 2026 miss but Q4 2025 beat, with Q2 2026 results pending. Cash flow from operations remains robust at $552 million in 2026, though net cash flow is negative. A $0.70 dividend for H1 2026 is scheduled, reflecting shareholder returns.
Outlook is positive due to strong fundamentals and 100% buy ratings from analysts, but risks include earnings volatility and negative net cash flow. The stock offers value with attractive valuation metrics and dividend yield, though investors should monitor Q2 earnings and cash flow trends for sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About TORM plc
TORM plc is one of the world's largest owners and operators of product tankers, specializing in the transportation of refined oil products like gasoline, jet fuel, and diesel. Operating under its integrated 'One TORM' model, the company maintains a modern, wholly-owned fleet of nearly 90 vessels. It is widely recognized by investors for its aggressive variable dividend policy, which returns a significant portion of its cash flow directly to shareholders during periods of high freight rates.
Read more on TRMD →
